Jia Luo

2.7k total citations
64 papers, 1.0k citations indexed

About

Jia Luo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jia Luo has authored 64 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in Jia Luo's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Research Studies (10 papers). Jia Luo is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Research Studies (10 papers). Jia Luo collaborates with scholars based in United States, China and United Kingdom. Jia Luo's co-authors include Maria E. Arcila, Jason C. Chang, Natasha Rekhtman, Robin Guo, Alexander Drilon, Matthew D. Hellmann, Jamie E. Chaft, Song Wu, J. Carl Barrett and Michiel S. van der Heijden and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Jia Luo

59 papers receiving 1.0k citations

Peers

Jia Luo

ONCOL

PRM

PFM

Guoshuang Shen China

Vanja Vaccaro Italy

Toshio Fujino Japan

Pierre Bohanes United States

Erwan Pencreach France

J.P. Delord France

Akira Ooki Japan

Anne‐Laure Pointet France

Preston D. Steen United States

Guoshuang Shen China

Jia Luo

538 ×1.0

ONCOL

356 ×0.8

PRM

298 ×0.9

219 ×0.8

73 ×0.7

PFM

Citations per year, relative to Jia Luo Jia Luo (= 1×) peers Guoshuang Shen

Countries citing papers authored by Jia Luo

Since Specialization

Citations

This map shows the geographic impact of Jia Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jia Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jia Luo more than expected).

Fields of papers citing papers by Jia Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jia Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jia Luo. The network helps show where Jia Luo may publish in the future.

Co-authorship network of co-authors of Jia Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Jia Luo. A scholar is included among the top collaborators of Jia Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jia Luo. Jia Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahadevan, Navin R., Paul K. Paik, Jamie E. Chaft, et al.. (2025). Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry. Clinical Cancer Research. 31(18). 3922–3931. 2 indexed citations

Li, Lin, Yuan Chen, Yan Liu, et al.. (2024). Gut microbiota: Implications in pathogenesis and therapy to cardiovascular disease (Review). Experimental and Therapeutic Medicine. 28(5). 427–427. 5 indexed citations

Mita, Monica, Alain C. Mita, Miguel A. Villalona‐Calero, et al.. (2024). Abstract PO4-18-07: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors. Cancer Research. 84(9_Supplement). PO4–18. 1 indexed citations

Luo, Jia, Paul K. Paik, Jamie E. Chaft, et al.. (2024). Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry.. Journal of Clinical Oncology. 42(16_suppl). 8553–8553. 1 indexed citations

Luo, Jia, Mark G. Evans, Tolulope Adeyelu, et al.. (2024). Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma. JCO Precision Oncology. 8(8). e2400334–e2400334. 2 indexed citations

Luo, Jia, Narjust Florez, Yanyan Lou, et al.. (2024). Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS ^G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precision Oncology. 8(8). e2300644–e2300644. 3 indexed citations

Wang, Pei, Hao Gong, Jia Luo, et al.. (2023). Wnt4 increases the thickness of the epidermis in burn wounds by activating canonical Wnt signalling and decreasing the cell junctions between epidermal cells. Burns & Trauma. 11. tkac053–tkac053. 5 indexed citations

Yu, Gang, Xiaolin Wang, Jia Luo, et al.. (2023). [Role of SPP1 in acute kidney injury induced by renal ischemia-reperfusion in rats].. PubMed. 43(11). 1947–1954. 1 indexed citations

Huang, Julianna, Luke Wojenski, Prafulla C. Gokhale, et al.. (2023). The BRD4–NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma. Cancer Research. 83(23). 3846–3860. 11 indexed citations

10.

Becker, Simone, et al.. (2023). Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report. JTO Clinical and Research Reports. 5(1). 100625–100625. 1 indexed citations

11.

Federico, Alessandro Di, Biagio Ricciuti, Joao V. Alessi, et al.. (2023). MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma. Journal of Thoracic Oncology. 18(11). S175–S175.

12.

Paik, Paul K., Jia Luo, Ni Ai, et al.. (2022). Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nature Communications. 13(1). 6095–6095. 13 indexed citations

13.

Luo, Jia, Song Wu, Hira Rizvi, et al.. (2022). Deciphering radiological stable disease to immune checkpoint inhibitors. Annals of Oncology. 33(8). 824–835. 24 indexed citations

14.

Beattie, Jason, Hira Rizvi, Jia Luo, et al.. (2021). Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 9(2). e001884–e001884. 39 indexed citations

15.

Luo, Jia, Jason Beattie, Hira Rizvi, et al.. (2021). Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. Journal of Thoracic Oncology. 16(10). 1759–1764. 74 indexed citations

16.

Zhang, Qu, Jia Luo, Song Wu, et al.. (2020). Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discovery. 10(12). 1842–1853. 221 indexed citations

17.

Alessi, Joao V., Biagio Ricciuti, Fangxin Hong, et al.. (2020). Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Journal for ImmunoTherapy of Cancer. 8(2). e001007–e001007. 40 indexed citations

18.

Guo, Robin, Jia Luo, Jason C. Chang, et al.. (2020). MET-dependent solid tumours — molecular diagnosis and targeted therapy. Nature Reviews Clinical Oncology. 17(9). 569–587. 210 indexed citations

19.

Luo, Jia, et al.. (2018). A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. European Journal of Cancer. 101. 143–151. 14 indexed citations

20.

Li, Qing, Xi Wei, Zhi-Wei Zhou, et al.. (2018). GADD45α sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level. Cell Death and Disease. 9(5). 524–524. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact